Celsion Corporation (CLSN) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Celsion Corporation (NASDAQ:CLSN) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.14), Briefing.com reports. Celsion Corporation had a negative net margin of 4,440.60% and a negative return on equity of 276.51%.

Shares of Celsion Corporation (NASDAQ:CLSN) opened at $2.12 on Tuesday. Celsion Corporation has a 1 year low of $1.24 and a 1 year high of $12.60.

TRADEMARK VIOLATION NOTICE: “Celsion Corporation (CLSN) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.truebluetribune.com/2017/11/14/celsion-corporation-clsn-issues-quarterly-earnings-results-misses-expectations-by-0-14-eps.html.

Several research firms recently issued reports on CLSN. Maxim Group restated a “hold” rating on shares of Celsion Corporation in a research note on Tuesday, August 15th. ValuEngine upgraded Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research downgraded Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.63.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Earnings History for Celsion Corporation (NASDAQ:CLSN)

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply